ClinicalTrials.gg

Program

BRAF V600E Inhibitor HLX208

Also written as “HLX208”, “[14C]HLX208” and “HLX 208”.

In Fosun Pharma’s pipeline, BRAF V600E. Its studies are mostly in Thyroid Carcinoma, Anaplastic · Colorectal Neoplasms · Histiocytosis, Langerhans-Cell · Carcinoma, Non-Small-Cell Lung · Brain Neoplasms, led by Fosun Pharma.

Furthest: phase 2, since Jul 27, 202112 company-led studies, 7 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma127 open or runningphase 2since Jul 27, 2021Jun 9, 2021none ahead
  • Named in Fosun Pharma’s own pipeline as HLX208 (BRAF V600E), phase 2, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2021First study: phase 1 study in Solid TumorFirst studyNCT04965220 · 220 planned · China
  2. Jul 27, 2021Phase 2 study in CRCNCT04984369 · 50 enrolled · China
  3. Sep 9, 20213 phase 2 studiesNCT05065398, NCT05092802, NCT05092815
  4. Oct 20, 20212 phase 2 studiesNCT05102292, NCT05114603
  5. Nov 9, 2021Phase 2 study in Colorectal NeoplasmsNCT05127759 · 25 enrolled · China
  6. Sep 2, 2022Phase 2 study in Solid TumorNCT05528406 · 30 planned
  7. Nov 15, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05641493 · 49 planned · China
  8. Apr 24, 2023Phase 1 study in Mass Balance Study in Healthy SubjectsNCT05841940 · 6 enrolled · China
  9. May 24, 2023Phase 1 study in NSCLCNCT05902728 · 20 enrolled · China

TargetBeta

“BRAF V600E”the company's pipeline, read by Claude · source

Other programs on BRAF

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440
tovorafenibruleday-one-biopharmaceuticals-incphase 38
belvarafenibruleHanmi Pharmaceuticalphase 26
claturafenibPfizerphase 12

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05902728NSCLC · China1CompletedDec 19, 202320
NCT05841940Mass Balance Study in Healthy Subjects · China1CompletedJul 15, 20236
NCT05641493Carcinoma, Non-Small-Cell Lung · China2RecruitingMar 4, 202549
NCT05528406Solid Tumor2Not yet recruitingOct 30, 202430
NCT05127759Colorectal Neoplasms · China2Active, not recruitingJan 30, 202425
NCT05114603Advanced Melanoma · China2UNKNOWNAug 30, 202330
NCT05102292Thyroid Carcinoma, Anaplastic · China2Active, not recruitingJun 30, 202425
NCT05092815Histiocytosis, Langerhans-Cell · China2Active, not recruitingJun 30, 202425
NCT05092802Brain Neoplasms · China2UNKNOWNMay 30, 202340
NCT05065398NSCLC · China2UNKNOWNJun 30, 202320
NCT04984369CRC · China2Active, not recruitingJun 15, 202450
NCT04965220Solid Tumor · China1RecruitingJun 30, 2024220

How it is read

Names in the registry

  • “HLX208”, 12 entries
  • “[14C]HLX208”, 1 entry
  • “HLX 208”, 1 entry
  • “HLX208+HLX10”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.